Read Summary

  1. Ndiya Ogba, PhD29,*
  1. From 1Stanford Cancer Institute; 2UCSF Helen Diller Family Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at John Hopkins; 4City of Hope Comprehensive Cancer Center; 5Dana-Farber/Brigham and Women’s Cancer Center; 6Moffitt Cancer Center; 7Fred & Pamela Buffett Cancer Center; 8The University of Texas MD Anderson Cancer Center; 9Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; 10University of Alabama at Birmingham Comprehensive Cancer Center; 11Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 12Roswell Park Comprehensive Cancer Center; 13Massachusetts General Hospital Cancer Center; 14Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 15Mayo Clinic Cancer Center; 16University of Michigan Comprehensive Cancer Center; 17University of Wisconsin Carbone Cancer Center; 18Fox Chase Cancer Center; 19The Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute; 20Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 21St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; 22Duke Cancer Institute; 23Vanderbilt-Ingram Cancer Center; 24Memorial Sloan Kettering Cancer Center; 25UC San Diego Moores Cancer Center; 26University of Colorado Cancer Center; 27Yale Cancer Center/Smilow Cancer Hospital; 28Huntsman Cancer Institute at the University of Utah; and 29National Comprehensive Cancer Network.


The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN Guidelines Panel meets at least annually to review comments from reviewers within the NCCN Member Institutions, examine relevant data, and reevaluate and update the recommendations. These NCCN Guidelines Insights summarize recent updates centered on treatment considerations for relapsed/refractory classic HL.


  • * Provided content development and/or authorship assistance.

  • Please Note

    The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes to the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further the understanding of these changes by summarizing salient portions of the NCCN Guideline Panel discussion, including the literature reviewed.

    These NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

    The full and most current version of these NCCN Guidelines are available at

    © National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

  • Disclosure of Relevant Financial Relationships

    The NCCN staff listed below discloses no relevant financial relationships:

    Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

    Individuals Who Provided Content Development and/or Authorship Assistance:

    Richard T. Hoppe, MD, Panel Chair, has disclosed that he has no relevant financial relationships.

    Ranjana H. Advani, MD, Panel Vice Chair, has disclosed that she receives grant/research support from Agensys, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Forty Seven Inc.; Genentech, Inc.; Infinity Pharmaceuticals, Inc.; Janssen Pharmaceutica Products, LP; Kura Oncology, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Pharmacyclics, Inc.; Regeneron Pharmaceuticals, Inc; Roche Laboratories, Inc; Seattle Genetics, Inc.; and Teva Pharmaceuticals Industries Ltd. She also receives consulting fees/honoraria from AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Genentech, Inc.; Gilead Sciences, Inc.; Juno Therapeutics, Inc.; NanoString Technologies, Inc.; Roche Laboratories, Inc; Seattle Genetics, Inc.; and Sutro Biopharma, Inc. She also serves as a scientific advisor for Cell Medica.

    Jennifer L. Burns, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.

    Ndiya Ogba, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

    This activity is supported by educational grants from AstraZeneca, Celldex Therapeutics, Celgene Corporation, Genentech, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc. This activity is supported by independent educational grants from AbbVie, Merck & Co., Inc. and NOVOCURE.

Print Friendly, PDF & Email